Nevertheless, the identification of the de novo GPHN mutation in a patient with a Dravet‐like syndrome is intriguing, since the GABAergic synapse is a well‐known major pathway for this phenotype: mutations in SCN1A, mainly expressed in inhibitory GABAergic interneurons, GABRA1, and GABRG2, all have previously been linked to Dravet syndrome (Hirose, 2014). This evidence concerns the gene GABRG2 and Dravet syndrome.